文献速递免疫规划传染病防控与疫情报告

非洲轮状病毒疫苗接种十年:拯救生命并改变腹泻疾病面貌

A decade of rotavirus vaccination in Africa - Saving lives and changing the face of diarrhoeal diseases: Report of the 12th African Rotavirus Symposium.
PubMed 文献 · Vaccine · 2021-03-26

非洲轮状病毒网络于2019年在南非举办第12届非洲轮状病毒研讨会,主题为非洲轮状病毒疫苗接种十年。会议回顾了全球及区域轮状病毒腹泻流行病学趋势、疫苗引入进展与安全性监测、非洲疫苗效果与影响,并讨论了新型疫苗研发及其他腹泻病原体监测研究。WHO协调的33个成员国监测网络报告,疫苗引入后5岁以下儿童急性胃肠炎住院率下降约40%。

要点

  • WHO预认证4种口服减毒轮状病毒疫苗:Rotarix、RotaTeq、Rotavac和RotaSiil。
  • 非洲疫苗引入后5岁以下儿童急性胃肠炎住院率下降约40%。
  • 非洲轮状病毒基因型多样性持续存在,地理和时间上均有变异。

核心结论

  • 非洲国家在常规免疫规划中使用轮状病毒疫苗已显现效果和对腹泻疾病负担的影响。
  • 部分国家失去Gavi资格及疫苗供应短缺对实现非洲轮状病毒免疫全覆盖构成重大挑战。
  • 目前无证据表明当前疫苗未覆盖的轮状病毒株可逃逸疫苗诱导的免疫。

研究设计与样本

  • 第12届非洲轮状病毒研讨会(ARS)于2019年7月30日至8月1日在南非约翰内斯堡举行,由非洲轮状病毒网络组织。

主要发现

  • 2006年至2018年间,WHO协调的非洲轮状病毒监测网络(AfrRSN)33个成员国中92,000名儿童报告,轮状病毒疫苗引入后5岁以下儿童急性胃肠炎住院率下降约40%。
  • 一项纳入2000年1月至2018年8月已发表数据的荟萃分析证实,使用轮状病毒疫苗的国家轮状病毒住院率大幅下降。
  • 非洲轮状病毒基因型多样性持续存在,地理和时间上均有变异。

关键数值与推荐

  • WHO目前预认证4种口服减毒轮状病毒疫苗:Rotarix、RotaTeq、Rotavac和RotaSiil。

临床怎么用

  • 非洲国家应将轮状病毒疫苗纳入常规国家免疫规划以降低腹泻疾病负担。
  • 需持续开展轮状病毒疫苗安全性监测和影响评估。
  • 应关注Gavi资格 transition 和疫苗供应短缺对免疫规划可持续性的影响。

局限性

  • 研讨会报告未提供原始研究数据或系统评价方法学细节。
  • 住院率下降约40%的数据来自监测网络报告,未提及置信区间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The African Rotavirus Network organised the 12th African Rotavirus Symposium (ARS) from 30 July to 1 August 2019 in Johannesburg, South Africa. The symposium theme "A decade of rotavirus vaccination in Africa - Saving lives and changing the face of diarrhoeal diseases", included sessions aimed at sharing ideas and expertise on prevention and control of diarrhoeal disease in Africa. Inter alia, the delegates reviewed global and regional epidemiological trends on rotavirus diarrhoea, progress and experiences on rotavirus vaccine introduction, including vaccine safety monitoring and impact in Africa, scientific advances in developing newer rotavirus vaccines, surveillance and research on other diarrhoeal pathogens, and providing an enabling environment for networking. Importantly, the 12th ARS served to commemorate the 20th anniversary of the African Rotavirus Network (AfrRN) coinciding with the 50th anniversary of the South African Medical Research Council. Four oral, live-attenuated rotavirus vaccines are currently prequalified by the WHO (Rotarix, RotaTeq, Rotavac and RotaSiil). African countries utilising rotavirus vaccines in routine national immunisation programmes are realising their effectiveness and impact on diarrhoeal disease morbidity. An ~40% reduction in hospitalisations of <5-year-olds with acute gastroenteritis following rotavirus vaccine introduction, was reported between 2006 and 2018 in 92,000 children from the WHO-coordinated African Rotavirus Surveillance Network (AfrRSN) comprising 33 Member States. This was corroborated by a meta-analysis of published data, sourced from January 2000 to August 2018 that reported substantial reductions in rotavirus hospitalisations in countries using rotavirus vaccines. However, it was highlighted that the transition of some countries from Gavi-eligibility and vaccine supply shortfalls present significant challenges to achieving the full impact of rotavirus immunization in Africa. The wide diversity of rotavirus genotypes continues in Africa, with variation observed both geographically and temporally. There is currently no evidence to suggest that the emergence of rotavirus strains not included in the current vaccines do escape vaccine-induced immunity.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mphahlele MJ, Groome MJ, Page NA, et al. A decade of rotavirus vaccination in Africa - Saving lives and changing the face of diarrhoeal diseases: Report of the 12th African Rotavirus Symposium. Vaccine. 2021. PMID: 33775436. doi:10.1016/j.vaccine.2021.03.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。